Abstract

Risk assessment in newly diagnosed multiple myeloma patients (NDMM) is the first and the most crucial determinant of treatment. With the utilization of FISH analysis as a part of routine practice, high risk Multiple Myeloma (MM) is defined as having at least one of the mutations related with poor prognosis including; t(4;14) t(14;16), t(14;20), del 17p, p53 mutation, gain 1q and del 1p. M-Smart MM risk stratification guideline by Mayo Clinic has proposed a concept similar to high grade lymphomas. Having two of the high risk genetic abnormalities were defined as double hit MM and having any three as triple hit MM. Based on these definitions which may bring a much more clinically relatable understanding in MM prognosis, we aimed to assess our database regarding these two concepts and their probable significance in terms of outcome and prognosis. We retrospectively evaluated 159 newly diagnosed multiple myeloma patients and their clinical course. Among these patients; twenty-four patients have one high risk determinant and also seven and two patients were classified as double hit MM and triple hit MM respectively. Overall survival (OS) of the patients with double hit MM was 6 months, 32.0 months for patients with single high risk abnormality and 57.0 months for patients with no high risk abnormality. Univariate analysis showed that Double Hit and Triple Hit MM is a predictive of low OS. Hazard Ratio of patients with one high risk abnormality was 1.42, double-hit MM patients was 5.55, and triple-hit MM patients was 7.3. Despite the development of novel drugs and their effects of prolonging survival, the treatment has not been individualized. Understanding the biology of each patient as a unique process will be the success of the treatment. As it is known that some MM patients harbor high risk genetic abnormalities according to FISH analysis, we can continue the argument that some patients bring an even higher risk and that can be defined as double or triple hit MM.

Details

Title
Concepts of Double Hit and Triple Hit Disease in Multiple Myeloma, Entity and Prognostic Significance
Author
Baysal Mehmet 1   VIAFID ORCID Logo  ; Demirci Ufuk 1 ; Umit Elif 1 ; Kirkizlar, Hakki Onur 1 ; Atli Emine Ikbal 2 ; Gurkan Hakan 2 ; Karaman, Gulsaran Sedanur 1 ; Volkan, Bas 1 ; Mail Cisem 2 ; Demir, Ahmet Muzaffer 1 

 Trakya University Faculty of Medicine, Department of Hematology, Edirne, Turkey (GRID:grid.411693.8) (ISNI:0000 0001 2342 6459) 
 Trakya University Faculty of Medicine, Department of Medical Genetics, Edirne, Turkey (GRID:grid.411693.8) (ISNI:0000 0001 2342 6459) 
Publication year
2020
Publication date
2020
Publisher
Nature Publishing Group
e-ISSN
20452322
Source type
Scholarly Journal
Language of publication
English
ProQuest document ID
2386859781
Copyright
© The Author(s) 2020. This work is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.